B7-33 Peptide – The Selective RXFP1 Agonist for Fibrosis Research

• Selective RXFP1 Agonism: B7-33 is distinguished as a functionally selective agonist for the RXFP1 receptor. Unlike H2-relaxin, it does not activate the RXFP2 receptor or stimulate cAMP production, allowing researchers to study RXFP1-mediated effects in isolation.
• Collagen Degradation & MMP-2: In cardiac and renal myofibroblast studies, B7-33 has shown high potency in increasing Matrix Metalloproteinase-2 (MMP-2). This enzyme is critical for the degradation of extracellular collagen, making the peptide a primary candidate for research into preventing and reversing organ fibrosis.
• pERK1/2 Signaling Pathway: B7-33 preferentially activates the pERK1/2 pathway over the cAMP pathway. This signaling is linked to cell cycle regulation and has been implicated in investigating chronic conditions like Alzheimer’s and cardiac remodeling.
• Heterodimer Interaction: Research suggests B7-33 may exert its activity through RXFP1–AT2R (Angiotensin II Type 2 Receptor) heterodimers. This specific interaction is hypothesized to be the mechanism behind its anti-fibrotic potential and its ability to modulate the cell cycle.
• Cardiovascular & Renal Health: Due to its ability to prevent the accumulation of fibrotic tissue without systemic side effects like excessive cAMP production, it is a leading subject in studies focused on long-term heart and kidney health.